SARS‐CoV‐2 variants and vulnerability at the global level

VP Chavda, AB Patel… - Journal of medical …, 2022 - Wiley Online Library
Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity …

Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world

VP Chavda, Q Yao, LK Vora, V Apostolopoulos… - Frontiers in …, 2022 - frontiersin.org
In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health …

Recent review of COVID-19 management: Diagnosis, treatment and vaccination

VP Chavda, S Vuppu, T Mishra, S Kamaraj… - Pharmacological …, 2022 - Springer
The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global …

Global impact of delta plus variant and vaccination

VP Chavda, V Apostolopoulos - Expert Review of Vaccines, 2022 - Taylor & Francis
The coronavirus, like all viruses, has mutated numerous times since it first appeared in
China in late 2019. Throughout the pandemic, a number of variants have surfaced, changing …

Therapeutic monoclonal antibodies for COVID-19 management: an update

VP Chavda, R Prajapati, D Lathigara… - Expert opinion on …, 2022 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena

VP Chavda, R Bezbaruah, M Athalye, PK Parikh… - Viruses, 2022 - mdpi.com
The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of
human coronavirus (CoV) that is held accountable for the current “coronavirus disease 2019 …

Adenoviral vector-based vaccine platform for COVID-19: Current status

VP Chavda, R Bezbaruah, D Valu, B Patel, A Kumar… - Vaccines, 2023 - mdpi.com
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the
21st century, claiming millions of lives and putting a huge burden on the global economy …

Is booster dose strategy sufficient for omicron variant of SARS-CoV-2?

VP Chavda, V Apostolopoulos - Vaccines, 2022 - mdpi.com
The Omicron variant of SARS-CoV-2 is emerging in communities where people were
previously infected with SARS-CoV-2 and are now being vaccinated, or where many people …

COVID-19 and vaccination: myths vs science

VP Chavda, Y Chen, J Dave, ZS Chen… - Expert Review of …, 2022 - Taylor & Francis
Introduction Several vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have been developed since the inception of the coronavirus disease 2019 …

Are nutraceuticals effective in COVID-19 and post-COVID prevention and treatment?

A Catalano, D Iacopetta, J Ceramella, ACD Maio… - Foods, 2022 - mdpi.com
The beginning of the end or the end of the beginning? After two years mastered by
coronavirus disease 19 (COVID-19) pandemic, we are now witnessing a turnaround. The …